IKT (Inhibikase Therapeutics) Total Liabilities: $5.71 Mil (As of Mar. 2026)


IKT Inhibikase Therapeutics Inc IKT
33 GF Score
Price $1.99
! 1 Warning Sign
View Full Analysis

What is Inhibikase Therapeutics Total Liabilities?

Inhibikase Therapeutics IKT +3.11% 33 Total Liabilities is $5.71 Mil as of Mar. 2026. GuruFocus rates IKT with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Inhibikase Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $5.71 Mil.

Inhibikase Therapeutics's quarterly Total Liabilities increased from Sep. 2025 ($6.70 Mil) to Dec. 2025 ($8.30 Mil) but then declined from Dec. 2025 ($8.30 Mil) to Mar. 2026 ($5.71 Mil).

Inhibikase Therapeutics's annual Total Liabilities increased from Dec. 2023 ($3.53 Mil) to Dec. 2024 ($3.73 Mil) and increased from Dec. 2024 ($3.73 Mil) to Dec. 2025 ($8.30 Mil).

Inhibikase Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Inhibikase Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inhibikase Therapeutics Total Liabilities Chart

Inhibikase Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 4.05 3.90 3.53 3.73 8.30

Inhibikase Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.55 8.80 6.70 8.30 5.71
IKT
33GF Score
Inhibikase Therapeutics Inc IKT
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inhibikase Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Inhibikase Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.301+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=8.30

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=181.205-172.904
=8.30

Inhibikase Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.712+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=5.71

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=173.332-167.62
=5.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $5.71 Mil mean?
Inhibikase Therapeutics (IKT) has a Total Liabilities of $5.71 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Inhibikase Therapeutics and its competitors.
Is Inhibikase Therapeutics' Total Liabilities too high?
Inhibikase Therapeutics' current Total Liabilities is $5.71 Mil. Overall, Inhibikase Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Inhibikase Therapeutics' Total Liabilities compare to FHTX and OBIO?
Inhibikase Therapeutics' Total Liabilities of $5.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Inhibikase Therapeutics and its competitors. Inhibikase Therapeutics's current Total Liabilities is $5.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibikase Therapeutics stock overvalued right now?
Inhibikase Therapeutics (IKT) has a current Total Liabilities of $5.71 Mil. The current Total Liabilities is $5.71 Mil. Inhibikase Therapeutics' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current Total Liabilities is $5.71 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inhibikase Therapeutics Business Description

Address 1000 N. West Street, Suite 1200, Wilmington, DE, USA, 19801
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
33GF Score

Get the complete analysis for IKT

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.99
Price